<DOC>
	<DOCNO>NCT00664599</DOCNO>
	<brief_summary>The purpose study find Rituximab improve severe ocular lesion Behcet 's Disease .</brief_summary>
	<brief_title>Rituximab Treatment Severe Ocular Manifestations Behcet 's Disease</brief_title>
	<detailed_description>To test single blind randomize control study efficacy Rituximab versus combination pulse cyclophosphamide azathioprine . Both group receive 0.5 mg/kg/daily prednisolone .</detailed_description>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Behcet 's Disease fulfil new International Criteria Behcet 's Disease Having active ocular lesion ( posterior and/or retinal vasculitis ) Resistant cytotoxic drug + prednisolone 0.5 mg/kg Visual acuity le 1/10 Snellen chart Antecedent allergic reaction component therapeutic regimen</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Ocular lesion , Visual Acuity , Retinal Vasculitis</keyword>
</DOC>